Navigation Links
Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
Date:8/11/2009

WELLESLEY HILLS, Mass., Aug. 11 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-07034 Therapeutics - CNS Phase 2 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

The PRX-07034 Therapeutics - CNS Phase 2 is a small molecule, oral 5HT6 antagonist for cognitive impairment associated with schizophrenia (CIAS). The Company has completed Phase 1 in obesity with racemic compound and completed Phase 1 with chiral compound. It has an open IND and a significant quantity of chiral API available.

The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on September 30, 2009.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... On May ... Aqua® Research Water Life Science® and international water advocate, was honored by Ashram, Inc. ... women in ancient Egypt who knelt on the banks of the Nile to fill ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... leader Mike Morrow-Fox . With over 20 years of experience in leading technology ... well as several years of university teaching, Morrow-Fox will be featured on ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... the launch of its brand equity product, Brandvantage. This breakthrough tool leaves ... landscape of modern consumer decision-making. The proprietary framework incorporates attitudes, behavior and ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a small ... single drawbridge, citizens formed an organization, Madeira Beach United, to oppose two development projects ... small town center to a high rise urban environment. , According to the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s ... to host their second pop-up shop for three consecutive weekends. The pop-up shop ... the Santa Barbara community, a community full of women who appreciate the most ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: